Navigation Links
Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2010 Financial Results and Reviews Recent Developments
Date:3/11/2011

al is uncertain; Arena's response to the complete response letter for the lorcaserin NDA may not be submitted when anticipated or the information provided in such response may not satisfy the FDA; the FDA may request other information prior to or after Arena resubmits the lorcaserin NDA or approval of the lorcaserin NDA; unexpected or unfavorable new data; risks related to commercializing new products; Arena's ability to obtain and defend its patents; the timing, success and cost of Arena's research and development programs; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies may not proceed at the time or in the manner Arena or others expect or at all; Arena's ability to obtain adequate funds; risks related to relying on collaborative agreements; the timing and receipt of payments and fees, if any, from collaborators; and satisfactory resolution of pending and any future litigation or other disagreements with others. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.Contact: Arena Pharmaceuticals, Inc.

Media Contact: Russo PartnersJack Lief

David Schull, PresidentPresident and CEO

david.schull@russopartnersllc.com858.717.2310Cindy McGeeManager, IR and Corporate Communications

Anthony J. Russo, Ph.D., CEO858.453.7200, ext. 1479

tony.russo@russopartnersllc.com212.845.4251www.arenapharm.com Arena Pharmaceuticals, Inc.Condensed Co
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
2. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
5. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
6. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
7. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
8. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
9. Critical Pharmaceuticals Enter Sustained Release hGH Arena
10. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
11. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 17, 2014  The law firm McElroy, Deutsch, ... it will serve as host for "Show Me ... Risks of Healthcare Reform," a one-day conference scheduled ... systems, reimbursement, compliance and enforcement in a marketplace ... Logo -  http://photos.prnewswire.com/prnh/20140916/146606 Logo -  http://photos.prnewswire.com/prnh/20140916/146607 ...
(Date:9/17/2014)... LEIPZIG, Germany , Sept. 17, ... has entered into an exclusive technology development partnership ... imaging agents to image CD4+ positive immune T ... ImaginAb,s capability to precisely diagnose and determine therapeutic ... areas. The ability to image CD4+ T-cells will ...
(Date:9/17/2014)... , Sept. 17, 2014   GS1 US ... to implement GS1 Standards to support the 2013 ... patient safety and security in the pharmaceutical supply ... Standards to U.S. Pharmaceutical Supply Chain Business Processes ... , was developed in collaboration with GS1 ...
Breaking Medicine Technology:Three Leading Healthcare Organizations Sponsor Conference to Examine Opportunities and Risks of Healthcare Reform for Providers 2ImaginAb Expands ImmunoPET Pipeline to Include CD4+ T-Cell Imaging 2New Healthcare Industry Guideline Delineates How to Implement GS1 Standards to Support Requirements of the 2013 Drug Supply Chain Security Act 2New Healthcare Industry Guideline Delineates How to Implement GS1 Standards to Support Requirements of the 2013 Drug Supply Chain Security Act 3New Healthcare Industry Guideline Delineates How to Implement GS1 Standards to Support Requirements of the 2013 Drug Supply Chain Security Act 4
... TEL-AVIV, Israel , March 15, 2010 Cheetah Medical, a,worldwide leader in noninvasive hemodynamic and cardiac output ... and also included Robert,Bosch Venture Capital (RBVC), MVM Life Science Partners (MVM) and existing,investors. , ... ... ...
... With heart disease continuing to be the No. 1 cause of death in the U.S., Atherotech Inc. has ... company is expanding its disease management services with the goal of helping physicians reduce death and disability from heart disease. ... ... , ...
Cached Medicine Technology:Cheetah Medical Closes $20 Million Series B Financing 2Cheetah Medical Closes $20 Million Series B Financing 3Cheetah Medical Closes $20 Million Series B Financing 4Cheetah Medical Closes $20 Million Series B Financing 5Cheetah Medical Closes $20 Million Series B Financing 6Atherotech Recruits Top Experts in Fight Against Heart Disease 2Atherotech Recruits Top Experts in Fight Against Heart Disease 3Atherotech Recruits Top Experts in Fight Against Heart Disease 4Atherotech Recruits Top Experts in Fight Against Heart Disease 5Atherotech Recruits Top Experts in Fight Against Heart Disease 6
(Date:9/18/2014)... September 18, 2014 MD Complete ... results without a prescription, announced today that SHAPE Magazine ... the “Best Peel” in its annual Beauty Awards. ... most effective beauty products as tested by SHAPE’s expert ... real, noticeable results. Among the thousands of beauty products ...
(Date:9/18/2014)... discount dental plans website allows consumers to search ... savings in their area prior to joining the plan. Consumers ... use the plan same day. , With so many different ... be difficult. With most dental plan websites it is very ... a particular zip code before joining the plan. , That ...
(Date:9/18/2014)... 2014 With the development of ... of adjusting human body physiology, preventing diseases, promoting ... with a variety of specific populations. In 2013, ... reached RMB187.4 billion, up 12.0% year on year, ... View Full Report at http://www.marketresearchreports.biz/analysis/223449 , ...
(Date:9/18/2014)... TX (PRWEB) September 18, 2014 ... independent freestanding emergency rooms in the United States, named ... its new Missouri City-Lakes facility. , “We are ... as facility medical director of our new Missouri City-Lakes ... of First Choice Emergency Room. , Dr. Harrison ...
(Date:9/18/2014)... 9Lover.com, an internationally well-known designer and leader ... big promotion for its maternity wedding outfits. Now, all ... discounted maternity wedding dresses on its website. ... global consumers. The company’s development manager believes the cheap ... delighted. The current special offer will last until September ...
Breaking Medicine News(10 mins):Health News:MD Complete Wins Shape Beauty Award for Best Peel 2Health News:Discount Dental Plans Allow Consumers to Search Thousands of Local Dentists, Compare Savings and Discounts, and Download a Printable Membership Card 2Health News:China Health Food Industry Size 2014 Market Analysis, Growth, Trends and Forecast Report 2017: MarketResearchReports.biz 2Health News:China Health Food Industry Size 2014 Market Analysis, Growth, Trends and Forecast Report 2017: MarketResearchReports.biz 3Health News:China Health Food Industry Size 2014 Market Analysis, Growth, Trends and Forecast Report 2017: MarketResearchReports.biz 4Health News:First Choice Emergency Room Announces Dr. Douglas J. Harrison as Medical Director of Missouri City - Lakes, Texas Facility 2Health News:Discounted Maternity Wedding Dresses For 2014 Introduced By 9Lover.com 2
... Reporter , THURSDAY, Jan. 5 (HealthDay News) -- Pediatric ... to lower the threshold for toxic lead exposure in ... and house paint, can permanently damage developing brains. ... Poisoning Prevention voted to recommend that the federal government ...
... of patients with mild-to-moderate asthma have persistently non-eosinophilic ... anti-inflammatory treatments, according to a new study. ... enrolled in nine clinical trials conducted by the ... eosinophils) was,found in only 36% of asthmatics not ...
... Mozes HealthDay Reporter , THURSDAY, Jan. 5 ... double their risk of developing a particularly advanced form ... large new European study suggests. The possible link ... (AMD), a significant cause of blindness in seniors. ...
... Proton therapy, a type of external beam radiation therapy, ... according to two new studies published in the January ... (Red Journal), the American Society for Radiation Oncology,s ... study, researchers at the University of Florida in Jacksonville, ...
... Jan. 5 (HealthDay News) -- Children and young adults ... for complications from the flu and should receive flu ... in Ohio in February 2011. Of the 130 ... young adults with neurological and neurodevelopmental conditions, 76 (58 ...
... cost paid for statins (drugs to lower cholesterol) in ... insurance is approximately 400 percent higher than comparable costs ... These findings, from the Boston University School of Medicine ... results of a comprehensive comparison of prescription drug costs ...
Cached Medicine News:Health News:Experts Endorse Lower Lead-Poisoning Threshold 2Health News:Experts Endorse Lower Lead-Poisoning Threshold 3Health News:A large subgroup of mild-to-moderate asthma is persistently non-eosinophilic 2Health News:Could Daily Aspirin Harm Seniors' Eyes? 2Health News:Could Daily Aspirin Harm Seniors' Eyes? 3Health News:Proton therapy effective prostate cancer treatment 2Health News:Study finds statin costs 400 percent higher in US compared to UK 2
... Swing doors, 8 shelves. Over-sized ... doors. Fluorescent interior lighting. Self-Contained System ... foot cord. Full One Year Warranty on ... Warranty on Compressor. Also available as ...
... Independent controls for Digital Thermostat and Digital ... steel. , Interiorwhite anodized aluminum with ... Oversized refrigeration (134A). , Temperature range ... self-closing doors. , Foamed-in-place polyurethane high ...
... The HC Series Large Capacity Refigerators ... embryos, semen, or biological samples at liquid-nitrogen ... holding times and capacities are available to ... Two low profile HCL models are also ...
... refrigerators from Taylor-Wharton are uniquely designed to ... box-type storage racks and the lower operating ... The RackSystems are available in four convenient ... 750 x 2ml vials to 4800 x ...
Medicine Products: